KRAS and neoplasm: Diaz et al. [31••] showed that by monitoring circulating tumour DNA in patients treated with panitumumab for initially KRAS wild-type tumours, the emergence of mutations in KRAS could be detected during the course of therapy resulting in acquired resistance.